New Companies
Thursday, 7/9, 10:37 AM
AstraZeneca's Wainua Fails a Big Heart Trial, Wiping About £19 Billion Off Its Value
- AstraZeneca shares fell about 9.5% after Wainua, a heart drug it is developing with Ionis, missed the main goal of a large late-stage trial.
- The drop erased roughly £19 billion (around $26 billion) of market value, a rare stumble for Europe's most valuable drugmaker and a reminder of how much rides on a single trial result.